Double-blind, Randomized, Vehicle- and Comparator-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of LAS41007 in the Treatment of Actinic Keratosis

NCT01265602 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

889

Enrollment

INDUSTRY

Sponsor class

Conditions

Actinic Keratosis

Interventions

DRUG: LAS41007
DRUG: LASW1510
DRUG: vehicle of LAS41007

Sponsor

Almirall, S.A.